Investor Presentaiton slide image

Investor Presentaiton

sanofi MenB strong phase 1/2 results demonstrate competitiveness and support move to next phase hSBA seroresponse rate¹ - Sanofi MenB vs Bexsero² Vaccine strains² Cross-protection against strains not in the vaccine³ MenB Formulation 1 MenB Formulation 3 hSBA seroresponse rate¹ - Sanofi MenB vs Trumenba Vaccine strains² MenB Formulation 1 MenB Formulation 3 Higher point estimates (>+15%) similar (+/- 15%) Cross-protection against strains not in the vacine³ Lower (<15%) > Sanofi formulations were well tolerated > All antigens are immunogenic Breadth of protection reaching expected level 1. hSBA seroresponse - % of participants with ≥ 4-fold rise of antibody titer from baseline 2. Tested strains exhibiting one of the Sanofi vaccine antigen 3. Tested strains exhibiting different antigens from the Sanofi vaccine 75 Vaccines Investor Event
View entire presentation